ClinicalTrials.gg
CompletedNCT05057949Z650Updated May 18, 2025

A Study to Evaluate Drug-Drug Interaction of Larotinib With Itraconazole and Rifampin in Healthy Adult Participants

A Phase 1 interventional study of Larotinib and Rifampin in Healthy Volunteers, sponsored by Sunshine Lake Pharma Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-05-18.

Sponsored by Sunshine Lake Pharma Co., Ltd. · Phase 1, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
32
Allocation
Non-randomized
Ages
18 Years to 50 Years
Sex
All
01

Study summary

The purpose of this study is to characterize the effect of rifampin (Part A) and itraconazole(Part B) on the single-dose pharmacokinetics (PK) of Larotinib in healthy adult participants.

Read the detailed description

The drug being tested in this study is called Larotinib (Z650). The study assessed the drug-drug interaction of Larotinib with either a strong cytochrome P-450 (CYP)3A inducer, rifampin (Part A) , or with a strong CYP3A inhibitor itraconazole (Part B) in healthy adult participants.

02

Conditions studied

  • Healthy Volunteers
03

In context

Lead sponsor

Sunshine Lake Pharma Co., Ltd. is the lead sponsor of 83 studies on the registry; 13 are open to participants now.

Of its 6 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. The was signed before the study, and the content, process and possible adverse reactions of the study were fully understood;
  2. Without Plan for pregnancy or pregnant within 6 months from screening to the last dose of the study drug;
  3. Healthy, adult, male or female, 18 - 55 years of age;
  4. Male subjects should weigh at least 50 kg and female subjects should weigh at least 45 kg. (BMI) ≥18.0 and ≤28.0 kg/m2;
  5. Subjects, who are healthy, as having no abnormalities in vital signs and physical examination.

Exclusion criteria

Exclusion Criteria:

  1. Average daily smoking >5 cigarettes in 3 months before the study;
  2. Known allergic reactions or to any of the study drug formulation(s).
  3. History of alcoholism(defined as Alcohol consumption of > 14 units/week);
  4. Those with positive urine drug screening or those with a history of drug abuse or drug use in the past five years ;
  5. Blood donation or significant blood loss (>450 mL) within 3 months prior to screening;
  6. Have dysphagia or have gastrointestinal, liver, or kidney disease (whether cured or not) that affects drug absorption or excretion within 6 months prior to screening;
  7. Have any medical condition that increases the risk of bleeding, such as hemorrhoids, acute gastritis, or stomach and duodenal ulcers ;
  8. Use of any prescription drugs, over-the-counter drugs, any vitamin products or herbal medicines in the 14 days prior to screening;
  9. Any drugs that changed the activity of liver drug enzymes, such as barbiturates and rifampicin, were taken within 30 days before screening;
  10. Have taken the following inhibitors or inducers of , CYP2C8, CYP2C19 and P-GP within 30 days before screening;
  11. Patients who had taken special diet (including pitaya, mango, grapefruit, etc.) or had strenuous exercise, or had other factors affecting drug absorption, distribution, metabolism and excretion, as judged by the researcher, within 14 days before screening ;
  12. Participants who have participated in any drug clinical trials within 3 months prior to screening and have used the test drug (subjects may be enrolled in the study if they dropped out of the study prior to dosing, i.e., were not randomized or received dosing) ;
  13. Abnormal abdominal ultrasonography, chest radiography, examination is , or the interval (QTcF) of ECG >470ms during screening period ;
  14. Female subjects were lactating or had positive blood pregnancy results at screening or check in;
  15. Laboratory examination is abnormal and clinically significant, or the following diseases (including but not limited to gastrointestinal, renal, liver, neurological, hematological, endocrine, tumor, lung, immune, psychiatric or cardiovascular and cerebrovascular diseases) are clinically significant as found within 12 months prior to screening;
  16. Viral hepatitis (including and C), antigen/antibody or treponema pallidum antibody was positive at screening;
  17. Acute illness or concomitant medication was occurred from the screening to the first administration of the experimental drug;
  18. Subjects who consume chocolate, any food or drink containing caffeine or rich in xanthine within 24 hours before taking the study drug;
  19. Alcohol breath test is positive at check-in.
  20. Subjects who received vaccination within 28 days prior to screening or who plan to receive vaccination during the trial ;
  21. The investigator deemed the subject unsuitable for this study for any reason
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Prevention
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
32 participants (actual)

Study arms

  • Experimental
    Part A, Treatment Sequence(Larotinib-Larotinib/Rifampin)

    Larotinib , capsules (150mg\*2+50mg\*1), at Hour 0 on Day 1 followed by an overnight fast. On Days 15 to 26, participants received rifampin 600 mg as capsules, orally, once daily (QD) and Larotinib 350 mg as capsules, orally was coadministered on Day 20. There was a washout period of 13 days between the two treatments.

    Drug: Larotinib · Drug: Rifampin

  • Experimental
    Part B, Treatment Sequence(Larotinib-Larotinib/itraconazole)

    Larotinib , capsules (150mg\*2+50mg\*1), at Hour 0 on Day 1 followed by an overnight fast. On Days 15 to Day 25, participants received itraconazole 200 mg solution, orally, once daily (QD) on Days 15 to Day 25 and a single oral dose of Larotinib 350 mg as capsule was coadministered on Day 19 (Treatment B). There was a washout period of 13 days between the two treatments.

    Drug: Larotinib · Drug: Itraconazole

Interventions

  • Larotinib Capsules

    Also known as: Z650

  • Rifampin Capsules

    Also known as: Rifampin Capsules

  • Itraconazole Capsules

    Also known as: Itraconazole Capsules

06

What researchers measure

Primary outcomes

  1. Cmax

    Maximum Observed Plasma Concentration of Larotinib

    Time frame: Day 1 pre-dose at multiple time points (up to 192 hours) post-dose

  2. AUC∞

    Area Under the Plasma Concentration-time Curve from Time 0 to Infinity, calculated using the observed value of the last quantifiable concentration for Larotinib

    Time frame: Day 1 pre-dose at multiple time points (up to 192 hours) post-dose

Secondary outcomes

  1. AUClast

    Area Under the Concentration-time Curve from Time 0 to the Time of the Last Quantifiable Concentration for Larotinib

    Time frame: Day 1 pre-dose at multiple time points (up to 192 hours) post-dose

  2. Tmax

    Time to Reach the Maximum Plasma Concentration (Cmax) for Larotinib

    Time frame: Day 1 pre-dose at multiple time points (up to 192 hours) post-dose

07

Study locations

1 site
  • First Hospital of Jilin University
    Changchun, Jilin 130000, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2021 to primary completion in Feb 2022, 2 months.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 31, 2021
First posted
Sep 27, 2021
StartActual
Nov 24, 2021
Primary completionActual
Feb 17, 2022
CompletionActual
Sep 28, 2023
Last update
May 18, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 18, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05057949
Responsible party
Sponsor
First posted
Sep 27, 2021
Start date
Nov 24, 2021
Primary completion
Feb 17, 2022
Completion
Sep 28, 2023
Last update
May 18, 2025

Study contacts

Yanhua Ding
principal investigator · The First Hospital of Jilin University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Larotinib Mesylate · Rifampin · Itraconazole

Start the discussion